Novartis: Amgen's Tsai appointed to lead drug development
(CercleFinance.com) - As it unveiled its Q1 results, Novartis today announced the appointment of Amgen's John Tsai as chief medical officer.
He will be responsible for developing At Novartis' pipeline of innovative medicines and biosimilars.
Roche also said yesterday that its generic drugs unit Sandoz has signed an agreement with Pear Therapeutics to offer prescription digital therapeutics for patients with substance use disorder and opioid use disorders.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
He will be responsible for developing At Novartis' pipeline of innovative medicines and biosimilars.
Roche also said yesterday that its generic drugs unit Sandoz has signed an agreement with Pear Therapeutics to offer prescription digital therapeutics for patients with substance use disorder and opioid use disorders.
Copyright (c) 2018 CercleFinance.com. All rights reserved.